Targeting Psychosis in Alzheimer’s Disease

The Bio Report by Levine Media Group

Apr 1, 202622:09Business

Alzheimer’s disease drug development has long focused on slowing memory loss, but for many families, the tipping point that makes home care impossible is not cognition—it is psychosis. Hallucinations and delusions in Alz...

Related Episodes

Continue listening to more episodes from The Bio Report.

How a Breast-Milk-Derived Peptide Could Change Bladder Cancer Care

Sep 23, 2026 - 26:00

For people with non-muscle-invasive bladder cancer, treatment can involve repeated procedures, a high ris...

Targeting Visceral Fat with RNA Therapeutics

Sep 16, 2026 - 29:11

GLP-1 therapies have dramatically reshaped obesity care, but the next generation of medicines may be judg...

Engineering T-Cell Engagers for Solid Cancers

Sep 9, 2026 - 31:59

T-cell engagers have delivered important advances in blood cancers, but extending their success to solid...

Resetting Severe Allergies at Their Cellular Source

Sep 2, 2026 - 33:17

For people with severe allergies and mast cell diseases, the risk of a dangerous reaction can shape every...

Innovating ADCs with Dual Targeting and Smarter Delivery

Aug 26, 2026 - 29:35

Antibody-drug conjugates have established themselves as an important cancer-treatment modality, but their...

Targeting the Brain’s Immune System in Alzheimer’s Disease

Aug 19, 2026 - 34:19

Alzheimer’s disease remains one of medicine’s most intractable challenges. While existing therapies may a...

How Gilead Is Building Durable Oncology and Immunology Franchises

Aug 12, 2026 - 38:31

Gilead today stands at an inflection point. Its HIV and broader virology business still account for rough...

Protecting the Brain After Stroke

Aug 5, 2026 - 29:16

Ischemic stroke remains one of the most devastating and resource‑intensive emergencies in medicine, with...